Acute Myeloid Leukemia Coverage From Every Angle
Advertisement
Advertisement

Recent News

EHA25: Early Results With Alvocidib Followed by Chemotherapy for Newly Diagnosed AML
EHA25 Virtual: 6-Month VIALE-C Update on Venetoclax With Low-Dose Cytarabine in AML
Early Blood Cell Counts and Survival After Treatment of Newly Diagnosed AML
EHA25 Virtual: 5-Year Follow-up on Novel Dual-Drug Formulation in AML
Using Patient-Reported Data to Predict Survival in AML
EHA25 Virtual: FLT3 Inhibitor Plus Chemotherapy for Younger Patients With AML
ASCO20: 1-Year ADMIRAL Trial Update on Gilteritinib in Resistant AML
AACR II: Race-Based Survival Differences in Patients With AML Living in Texas
EHA25 Virtual: Venetoclax Plus Low-Dose Cytarabine for Older Adults With AML
First-in-Class Immunotherapy With Azacitidine Under Study in AML
FDA Approves Gemtuzumab Ozogamicin for Pediatric CD33-Positive AML
EHA25 Virtual: Azacitidine Versus Fludarabine Plus Cytarabine in Elderly Patients With AML
EHA25 Virtual: Venetoclax Plus Azacitidine in Older Patients With AML Who Are Ineligible for Intensive Therapy
ASCO20: Ivosidenib and Venetoclax in Treatment of IDH1-Mutated AML
ASCO20: Escalated Dosing Schedule of CC-486 in Patients With AML in First Relapse
ASCO20: Enasidenib Plus Azacitidine in Newly Diagnosed Mutant-IDH2 AML
ASCO20: Is Palliative Care of Benefit in Patients With High-Risk AML?
ASCO20: Adding Venetoclax to Cytarabine in Older Patients With AML
Using CRISPR Technology to Identify Key Regulating Proteins in AML
Venetoclax Plus Azacitidine for Younger Patients With Acute Leukemias
Combining Venetoclax and TKI in Ph-Positive Advanced Myeloid Leukemias
COVID-19 and AML: Case Report of Toddler With Severe Therapy-Induced Immunosuppression
Comparing Induction Regimens in Favorable-Risk Patients With AML
DDW 2020: Platelet Threshold and Adverse Events After Endoscopy in SCT Recipients
AACR 2020: Potential Correlation Between TP35 Abnormalities and Immune Subtypes of AML
Oral Azacitidine Granted Priority Review for Patients With AML in Remission
Myeloablative Versus Reduced-Intensity Conditioning Before Transplantation in AML
CPX-351 Versus Standard Chemotherapy for AML With Myelodysplasia-Related Changes
Hedgehog Pathway Inhibitor Plus Azacitidine in Newly Diagnosed AML
ACC 2020: Risk of Cardiovascular Events in Patients With Acute Myeloid Leukemia
Impact of COVID-19 Pandemic on Patients With AML
Managing Adults With AML: Updated ESMO Clinical Practice Guidelines
Can Genetic Mutations Predict Outcomes From Transplantation in AML?
Effects of NRAS and KRAS Mutations on Survival in Patients With Acute Myeloid Leukemia
Maintenance Therapy With Oral Azacitidine in AML
Update on New Generation of Precision Medicine Protocols in Treating AML
Identification of Mutational Constellations in AML
ATRA Plus Decitabine in Nonfit Elderly Patients With Acute Myeloid Leukemia
Characterization of Resistant AML After Venetoclax and Hypomethylation Failure
Inducing Cytotoxicity in Acute Myeloid Leukemia Cells With Novel Combination
Individualization of Therapy for AML Based on Geriatric Assessment and Genetic Profiling
IDH2 Inhibition Plus Azacitidine in IDH2 -Mutant AML
Does Time From Diagnosis to Treatment Affect Outcomes in Patients With AML?
ASH 2019: A Comparison of Clinical Outcomes by Hospital Volume for Patients with Acute Myeloid Leukemia
Vosaroxin Plus Infusional Cytarabine in First-Line Treatment of AML
Phase I Findings on Novel Immunotherapy for Resistant AML
Addition of Gemtuzumab Ozogamicin to Induction Therapy in AML


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.